guest ::
| Home > Publications database > Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. > print |
| Home > Publications database > Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. > print |
| 001 | 132842 | ||
| 005 | 20240228143510.0 | ||
| 024 | 7 | _ | |a 10.1016/j.canlet.2016.08.007 |2 doi |
| 024 | 7 | _ | |a pmid:27524505 |2 pmid |
| 024 | 7 | _ | |a 0304-3835 |2 ISSN |
| 024 | 7 | _ | |a 1872-7980 |2 ISSN |
| 024 | 7 | _ | |a altmetric:17890332 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2018-00485 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Weber, Tobias |b 0 |
| 245 | _ | _ | |a Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2016 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1525761388_10339 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Radioimmunotherapy is considered as treatment option in recurrent and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). To overcome the dose limiting bone marrow toxicity of IgG-based radioimmunoconjugates (RICs), we modified a humanized diabody with 5-, 10-, or 20-kDa polyethylene glycol (PEG) for CD22-targeted radioimmunotherapy using the low-energy β-emitter lutetium-177 ((177)Lu). A favorable pharmacokinetic profile was observed for the 10-kDa-PEG-diabody in nude mice being xenografted with subcutaneous human Burkitt lymphoma. Even at high doses of 16 MBq this diabody RIC was well tolerated by NOD Rag1(null) IL2rγ(null) (NRG) mice and did not reveal signs of organ long-term toxicity 80 days post injection. Combination therapy of the diabody RIC with unconjugated anti-CD20 Rituximab demonstrated therapeutic efficacy in established disseminated mantle cell lymphoma xenograft models. When compared with the combination of the IgG formatted (177)Lu anti-CD22 antibody and Rituximab, dual targeted therapy with the diabody RIC achieved an improved reduction of disease burden in the first nine days following treatment. The data indicate that the PEGylated anti-CD22 diabody may have potential for extending the repertoire of radiopharmaceuticals for the treatment of patients with B-NHL. |
| 536 | _ | _ | |a 315 - Imaging and radiooncology (POF3-315) |0 G:(DE-HGF)POF3-315 |c POF3-315 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Antibodies, Bispecific |2 NLM Chemicals |
| 650 | _ | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM Chemicals |
| 650 | _ | 7 | |a CD22 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Forkhead Transcription Factors |2 NLM Chemicals |
| 650 | _ | 7 | |a Homeodomain Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Il2rg protein, mouse |2 NLM Chemicals |
| 650 | _ | 7 | |a Immunoconjugates |2 NLM Chemicals |
| 650 | _ | 7 | |a Immunoglobulins, Intravenous |2 NLM Chemicals |
| 650 | _ | 7 | |a Interleukin Receptor Common gamma Subunit |2 NLM Chemicals |
| 650 | _ | 7 | |a Radioisotopes |2 NLM Chemicals |
| 650 | _ | 7 | |a Sialic Acid Binding Ig-like Lectin 2 |2 NLM Chemicals |
| 650 | _ | 7 | |a Whn protein |2 NLM Chemicals |
| 650 | _ | 7 | |a RAG-1 protein |0 128559-51-3 |2 NLM Chemicals |
| 650 | _ | 7 | |a Rituximab |0 4F4X42SYQ6 |2 NLM Chemicals |
| 650 | _ | 7 | |a Lutetium |0 5H0DOZ21UJ |2 NLM Chemicals |
| 700 | 1 | _ | |a Bötticher, Benedikt |b 1 |
| 700 | 1 | _ | |a Arndt, Michaela |0 P:(DE-He78)25866e5f0faaf24f74afbfa0b1708129 |b 2 |u dkfz |
| 700 | 1 | _ | |a Mier, Walter |b 3 |
| 700 | 1 | _ | |a Sauter, Max Benedikt |0 P:(DE-He78)a27964412d8159e07c55f8105401cb0f |b 4 |u dkfz |
| 700 | 1 | _ | |a Exner, Evelyn |b 5 |
| 700 | 1 | _ | |a Keller, Armin |b 6 |
| 700 | 1 | _ | |a Krämer, Susanne |b 7 |
| 700 | 1 | _ | |a Leotta, Karin |0 P:(DE-He78)c1b2ff9645588258d53aea1ccce6ddcf |b 8 |u dkfz |
| 700 | 1 | _ | |a Wischnjow, Artjom |b 9 |
| 700 | 1 | _ | |a Grosse-Hovest, Ludger |b 10 |
| 700 | 1 | _ | |a Strumberg, Dirk |b 11 |
| 700 | 1 | _ | |a Jäger, Dirk |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |b 12 |u dkfz |
| 700 | 1 | _ | |a Gröne, Hermann-Josef |0 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91 |b 13 |u dkfz |
| 700 | 1 | _ | |a Haberkorn, Uwe |0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |b 14 |u dkfz |
| 700 | 1 | _ | |a Brem, Gottfried |b 15 |
| 700 | 1 | _ | |a Krauss, Jürgen |b 16 |
| 773 | _ | _ | |a 10.1016/j.canlet.2016.08.007 |g Vol. 381, no. 2, p. 296 - 304 |0 PERI:(DE-600)2004212-7 |n 2 |p 296 - 304 |t Cancer letters |v 381 |y 2016 |x 0304-3835 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:132842 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)25866e5f0faaf24f74afbfa0b1708129 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)a27964412d8159e07c55f8105401cb0f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)c1b2ff9645588258d53aea1ccce6ddcf |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |2 G:(DE-HGF)POF3-300 |v Imaging and radiooncology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER LETT : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCER LETT : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l Angewandte Tumor-Immunität |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G010-20160331 |k G010 |l Geschäftsstelle |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)G130-20160331 |k G130 |l Zelluläre und Molekulare Pathologie |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)E060-20160331 |k E060 |l KKE Nuklearmedizin |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G010-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G130-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|